Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Expected to Post Earnings of -$0.66 Per Share

Brokerages predict that Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPHGet Rating) will post earnings per share (EPS) of ($0.66) for the current quarter, according to Zacks. Seven analysts have made estimates for Deciphera Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.73) and the highest is ($0.55). Deciphera Pharmaceuticals reported earnings of ($1.21) per share during the same quarter last year, which indicates a positive year over year growth rate of 45.5%. The company is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Deciphera Pharmaceuticals will report full year earnings of ($2.62) per share for the current year, with EPS estimates ranging from ($2.95) to ($2.23). For the next year, analysts expect that the business will post earnings of ($1.70) per share, with EPS estimates ranging from ($3.02) to ($0.34). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals (NASDAQ:DCPHGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.03. The company had revenue of $29.22 million during the quarter, compared to the consensus estimate of $27.17 million. Deciphera Pharmaceuticals had a negative net margin of 279.96% and a negative return on equity of 79.96%. The company’s revenue for the quarter was up 16.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.06) earnings per share.

Separately, Barclays downgraded shares of Deciphera Pharmaceuticals from an “equal weight” rating to an “underweight” rating and lowered their price target for the stock from $11.00 to $6.00 in a report on Monday, February 28th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $23.11.

Shares of NASDAQ:DCPH traded up $0.35 during trading on Monday, hitting $10.31. 1,026,096 shares of the company were exchanged, compared to its average volume of 1,462,250. The business’s 50 day moving average is $9.64 and its 200-day moving average is $10.00. The company has a market capitalization of $682.73 million, a P/E ratio of -2.11 and a beta of 1.41. Deciphera Pharmaceuticals has a 1-year low of $6.51 and a 1-year high of $11.47.

In related news, major shareholder Brightstar Associates Llc acquired 1,478,978 shares of the firm’s stock in a transaction that occurred on Friday, April 29th. The stock was acquired at an average cost of $10.00 per share, for a total transaction of $14,789,780.00. Following the completion of the acquisition, the insider now directly owns 18,051,348 shares of the company’s stock, valued at approximately $180,513,480. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 3,718 shares of company stock valued at $33,648 over the last 90 days. 4.10% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Lazard Asset Management LLC bought a new stake in Deciphera Pharmaceuticals during the first quarter valued at $57,000. Mariner LLC boosted its position in Deciphera Pharmaceuticals by 6.6% during the first quarter. Mariner LLC now owns 22,472 shares of the company’s stock valued at $208,000 after acquiring an additional 1,401 shares during the last quarter. First Trust Advisors LP boosted its position in Deciphera Pharmaceuticals by 178.6% during the first quarter. First Trust Advisors LP now owns 41,192 shares of the company’s stock valued at $382,000 after acquiring an additional 26,408 shares during the last quarter. Federated Hermes Inc. boosted its position in Deciphera Pharmaceuticals by 125.5% during the first quarter. Federated Hermes Inc. now owns 1,959,078 shares of the company’s stock valued at $18,161,000 after acquiring an additional 1,090,368 shares during the last quarter. Finally, Ergoteles LLC boosted its position in Deciphera Pharmaceuticals by 266.1% during the first quarter. Ergoteles LLC now owns 43,900 shares of the company’s stock valued at $407,000 after acquiring an additional 31,908 shares during the last quarter. 87.97% of the stock is currently owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Company Profile (Get Rating)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.

Featured Stories

Get a free copy of the Zacks research report on Deciphera Pharmaceuticals (DCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.